Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
128940KOSPI·Jul 29, 2025
2Q25 review: Revenue misses, OP beats
Mirae Asset Securities published a company analysis report on Hanmi Pharm. Co., Ltd. (128940) titled "2Q25 review: Revenue misses, OP beats".
Summary
Covers Hanmi Pharm. Co., Ltd. (128940).
Covered stock
More on 128940
Roche��s answer to Eli Lilly and Novo NordiskMirae Asset Securities · Aug 26, 2026Focus on Beijing Hanmi��s recovery and pipeline progressMirae Asset Securities · Jul 29, 2026Eli Lilly deal adds to pipeline valueMirae Asset Securities · Jun 04, 2026Sailing With LillyKB Securities · Jun 02, 2026Initiating Coverage: Core Business Recovery; Obesity, R&D NextKB Securities · May 27, 2026First Korean pharma to translate the obesity theme into earningsMirae Asset Securities · Feb 06, 2026Focus on potential recovery in quarterly earnings and June ADA eventMirae Asset Securities · Feb 05, 2025